Axsome Therapeutics, Inc.
Quick facts
Marketed products
- AXS-05 · Psychiatry/Neurology
AXS-05 is a combination of dextromethorphan and bupropion that enhances serotonergic and noradrenergic neurotransmission while modulating NMDA receptor activity.
Phase 3 pipeline
- AXS-02 · Neurology / Pain Management
AXS-02 is a combination of dextromethorphan and quinidine that enhances NMDA receptor antagonism and sigma-1 receptor modulation to reduce neuropathic pain. - AXS-02 (oral zoledronate) · Bone metabolism / Oncology
AXS-02 is an oral formulation of zoledronate, a bisphosphonate that inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway. - AXS-07 · Neurology
AXS-07 is a combination of melitracen (a tricyclic compound) and rizatriptan that works synergistically to treat acute migraine by enhancing serotonergic activity and providing rapid symptom relief. - AXS-07 (meloxicam-rizatriptan) · Neurology
AXS-07 combines meloxicam (an NSAID) with rizatriptan (a 5-HT1B/1D receptor agonist) to treat acute migraine by reducing inflammation and constricting cranial blood vessels. - AXS-12 (Reboxetine) · Psychiatry / Neurology
Reboxetine is a selective norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the brain by blocking its reuptake at the presynaptic neuron. - AXS-14 (Esreboxetine) · Psychiatry / Neurology
Esreboxetine is a norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the central nervous system by blocking its reuptake at the presynaptic neuron.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: